Budesonide is a corticosteroid that decreases inflammation in the digestive tract associated with diarrhea. It is a treatment option for Crohn's disease. Budesonide has been studied as prophylaxis for immune checkpoint inhibitor related enterocolitis. Research findings do not support Budesonide prophylaxis in this setting.
Vedolizumab is an integrin receptor antagonist indicated for treatment of inflammatory bowel disease. It has been studied in the treatment of immune-mediated diarrhea and colitis with favorable results in response, reduced hospitalizations and shorter steroid use duration.
Modification of dietary fiber has been studied for management of cancer treatment-related diarrhea and gastrointestinal toxicity.